|
Erasca, Inc. (ERAS) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Erasca, Inc. (ERAS) Bundle
Sparen Sie Zeit und verbessern Sie die Präzision mit unserem (ERAS) DCF -Taschenrechner! Mit der Verwendung von Real Erasca, Inc. Daten und anpassbaren Annahmen ermöglichen dieses Tool Sie, Erasca, Inc. wie ein erfahrener Investor zu prognostizieren, zu analysieren und zu bewerten.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -13.0 | -101.1 | -121.9 | -240.2 | -121.3 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .3 | .5 | .8 | 2.6 | 3.7 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -13.3 | -101.7 | -122.8 | -242.8 | -125.0 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 50.4 | 118.7 | 459.2 | 435.6 | 312.4 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 1.4 | .9 | 4.7 | 23.0 | 2.0 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.6 | -38.7 | -18.9 | -16.6 | -1.8 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -11.9 | -173.1 | -150.1 | -238.2 | -125.0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -10.8 | -211.7 | -164.3 | -233.7 | -144.1 | -2.0 | .0 | .0 | .0 | .0 |
| WACC, % | 8.29 | 8.39 | 8.39 | 8.37 | 8.39 | 8.37 | 8.37 | 8.37 | 8.37 | 8.37 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | -37 | |||||||||
| Equity Value | 35 | |||||||||
| Diluted Shares Outstanding, MM | 150 | |||||||||
| Equity Value Per Share | 0.24 |
What You Will Get
- Comprehensive ERAS Financials: Access historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Explore various scenarios to assess Erasca's future performance.
- User-Friendly Design: Designed for professionals but easy for newcomers to navigate.
Key Features
- 🔍 Real-Life ERAS Financials: Pre-filled historical and projected data for Erasca, Inc. (ERAS).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) such as WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Erasca’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Erasca’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- 1. Access the Template: Download and open the Excel file featuring Erasca, Inc.'s (ERAS) preloaded data.
- 2. Modify Assumptions: Adjust critical inputs such as growth projections, WACC, and capital expenditures.
- 3. See Results Instantly: The DCF model automatically calculates the intrinsic value and NPV.
- 4. Explore Scenarios: Evaluate multiple forecasts to assess various valuation outcomes.
- 5. Present with Assurance: Deliver professional valuation insights to back your decisions.
Why Choose This Calculator for Erasca, Inc. (ERAS)?
- Designed for Experts: A sophisticated tool tailored for analysts, CFOs, and industry consultants.
- Accurate Financials: Erasca’s historical and projected financial data preloaded for precision.
- Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
- Comprehensive Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance ensures a smooth experience throughout the process.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for portfolio assessments of Erasca, Inc. (ERAS).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within their organizations.
- Consultants and Advisors: Deliver precise valuation insights to clients interested in Erasca, Inc. (ERAS) stock.
- Students and Educators: Utilize real-world data to practice and instruct on financial modeling techniques.
- Biotech Enthusiasts: Gain insights into how biotech firms like Erasca, Inc. (ERAS) are valued in the investment landscape.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Erasca, Inc. (ERAS) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Erasca, Inc. (ERAS).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.